Incidence of Delayed Bleeding among Patients Continuing Antithrombotics during Gastric Endoscopic Submucosal Dissection.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
2019
Historique:
entrez: 5 10 2019
pubmed: 5 10 2019
medline: 19 12 2019
Statut: ppublish

Résumé

objective In patients continuing antithrombotics, delayed bleeding after gastric endoscopic submucosal dissection (ESD) is a severe complication. Vonoprazan (VPZ) exerts a rapid, potent, and long-lasting antacid effect compared with traditional proton-pump inhibitors (PPIs). This study aimed to compare the incidence of delayed bleeding after gastric ESD between the use of VPZ and PPIs in patients continuing antithrombotics. Methods In this retrospective analysis, we examined 71 patients with 101 lesions treated with traditional PPIs (PPI group) and 59 patients with 90 lesions treated with VPZ (VPZ group). After 2 days (day 0 and 1) of intravenous PPI administration, either an oral PPI or VPZ was administered from postoperative day 2 to 8 weeks after ESD. We assessed the incidence of overall delayed bleeding as well as bleeding that occurred from day 2 until 8 weeks after ESD. Results There was no significant difference in the use of antithrombotic agents between the groups. Overall delayed bleeding occurred 13 times (18%) in 9 patients in the PPI group and 18 times (31%) in 17 patients in the VPZ group (p=0.10). Bleeding from day 2 until 8 weeks after ESD occurred 12 times (17%) in 9 patients in the PPI group and 8 times (14%) in 8 patients in the VPZ group. Conclusion Even with a potent antacid agent, such as VPZ, the incidence of delayed bleeding was high in patients undergoing ESD with continuous antithrombotic agents.

Identifiants

pubmed: 31582592
doi: 10.2169/internalmedicine.2754-19
pmc: PMC6815908
doi:

Substances chimiques

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine 0
Anti-Ulcer Agents 0
Fibrinolytic Agents 0
Proton Pump Inhibitors 0
Pyrroles 0
Sulfonamides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2759-2766

Références

Aliment Pharmacol Ther. 2015 Sep;42(6):719-30
pubmed: 26193978
Digestion. 2018;97(2):170-176
pubmed: 29310111
Gastrointest Endosc. 2012 Apr;75(4):719-27
pubmed: 22317881
Dig Endosc. 2017 Jan;29(1):57-64
pubmed: 27492962
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastric Cancer. 2014;17(3):489-96
pubmed: 24142107
World J Gastrointest Endosc. 2016 Nov 16;8(19):716-722
pubmed: 27909552
Dig Endosc. 2016 Jan;28(1):3-15
pubmed: 26234303
Dig Endosc. 2017 Jul;29(5):576-583
pubmed: 28267236
Dig Endosc. 2014 Jan;26(1):1-14
pubmed: 24215155
J Gastroenterol. 2019 Feb;54(2):122-130
pubmed: 29943163
Dig Dis Sci. 2018 Apr;63(4):974-981
pubmed: 29464587
J Gastrointestin Liver Dis. 2017 Dec;26(4):363-368
pubmed: 29253050
Endoscopy. 2012 Feb;44(2):114-21
pubmed: 22271021
Endoscopy. 2015 Jul;47(7):632-7
pubmed: 25590184
Gastroenterol Res Pract. 2018 Feb 18;2018:1615092
pubmed: 29670650
Aliment Pharmacol Ther. 2016 Sep;44(6):583-91
pubmed: 27464849
Endosc Int Open. 2015 Feb;3(1):E31-8
pubmed: 26134769
Endoscopy. 2008 Mar;40(3):179-83
pubmed: 18322872
Gastric Cancer. 2017 Jan;20(1):207-214
pubmed: 26754296
Gastric Cancer. 2008;11(1):47-52
pubmed: 18373177
Dig Endosc. 2016 May;28(4):363-378
pubmed: 26900095
Surg Endosc. 2017 Apr;31(4):1746-1753
pubmed: 27530896
Gastroenterol Res Pract. 2013;2013:365830
pubmed: 23843783
Scand J Gastroenterol. 2018 Feb;53(2):243-251
pubmed: 29214885
Gastric Cancer. 2018 Jan;21(1):114-123
pubmed: 28224238
Endoscopy. 2016 Apr;48(4):385-402
pubmed: 26890676
Intern Med. 2019 Jan 15;58(2):159-166
pubmed: 30210115
Gastric Cancer. 2018 Jul;21(4):696-702
pubmed: 29357012

Auteurs

Naomi Kakushima (N)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Hiroyuki Ono (H)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Kohei Takizawa (K)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Masaki Tanaka (M)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Noboru Kawata (N)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Masao Yoshida (M)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Katsuyuki Murai (K)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Yohei Yabuuchi (Y)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Yoshihiro Kishida (Y)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Sayo Ito (S)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Kenichiro Imai (K)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Kinichi Hotta (K)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Hirotoshi Ishiwatari (H)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Hiroyuki Matsubayashi (H)

Division of Endoscopy, Shizuoka Cancer Center, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH